COO

The Cooper Companies, Inc.

Fundamental data last updated:November 5, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Medical - Instruments & Supplies

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

12/03/2026

Business Summary

The Cooper Companies, Inc. (COO) operates as a global medical device firm, primarily focused on developing, producing, and distributing products through two distinct business units: CooperVision and CooperSurgical. CooperVision specializes in contact lenses. Their product range includes spherical lenses for common vision issues like nearsightedness and farsightedness, as well as advanced lenses such as toric for astigmatism, multifocal for presbyopia, and specialized options addressing myopia, dry eyes, and eye fatigue. These vision correction solutions are available across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Meanwhile, CooperSurgical is dedicated to women's and family health, providing a wide array of medical devices, fertility treatments, genetic testing, diagnostic tools, and contraceptives to healthcare providers and patients globally. This segment's offerings encompass various surgical and office-based products like PARAGARD (an IUD), uterine manipulators, retractors, and closure devices. It also delivers comprehensive fertility services, including specialized consumables, equipment, embryo services, and preimplantation genetic screening. Established in 1958, The Cooper Companies, Inc. is headquartered in San Ramon, California.

 


Analyze COO on TradingView

VALUATION

P/E

20.92

Market Cap ($M USD)

$11.66B

Forward P/E

13.10

PEG

6.30

PRICE TO SALES

2.75

PRICE TO BOOK

1.42

EV / EBITDA

15.43

5-Year Average P/E

Free Cash Flow Yield

5.82%

DCF Value

$54.68

Graham Number

$53.45

Price to FCF

17.19

EV to FCF

20.72

Earnings Yield

4.81%

FCF Yield

5.82%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

$2.95

Next Year EPS Growth Estimate

$4.68

Next Year Revenue Growth Estimate

$4.41B

Return on Equity (ROE)

6.88%

FREE CASH FLOW

Operating Margin

12.85%

Debt-to-Equity

0.31

Piotroski F-Score

7

Altman Z-Score

3.02

Return on Invested Capital (ROIC)

4.76%

Current Ratio

1.22

Quick Ratio

0.73

Net Debt to EBITDA

2.62

Interest Coverage

5.76

Gross Profit margin

63.64%

FCF PER SHARE

$3.51

REVENUE PER SHARE

$21.91

Analyze COO on TradingView

Gainseekers Quantitative Analysis

Summary

The market seems to be mispricing The Cooper Companies, Inc., with its snapshot price trading above its DCF value and Graham Number. The Forward P/E of 13.50 suggests potential undervaluation relative to future earnings, while the Earnings Yield of 4.82% indicates moderate income generation. The Altman Z-score of 3.01 signals financial stability, reducing bankruptcy risk. However, the stock’s valuation metrics, such as Price/Sales and EV to EBITDA, suggest a premium that may not be justified by its current financial performance.

AI Exposure / Tech Reliance

Operating in the Medical Instruments & Supplies industry, The Cooper Companies is well-positioned to integrate AI and modern tech advancements. This sector's reliance on precision and innovation provides a fertile ground for AI-driven efficiencies. Their ability to adapt could enhance operational effectiveness and product development.

The Bull Case

For the value or GARP investor, The Cooper Companies presents an intriguing opportunity. With a Piotroski F-Score of 7, the company demonstrates strong financial health. Its ROIC of 4.76% and FCF Yield of 5.83% highlight efficient capital use and cash generation. The robust operating margin of 12.85% underscores pricing power, suggesting management's ability to maintain profitability even in competitive markets.

The Bear Case

Despite its strengths, the stock faces structural risks. The Price/Book ratio of 1.42 and Price/Sales of 2.74 indicate a potentially overvalued position relative to its book and sales values. The EV to FCF ratio of 20.67 suggests that investors are paying a high premium for future cash flows. Additionally, the stock's proximity to its 52-week high raises concerns about technical overextension.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$65.11

Institutional Ownership %

1-Year Beta

0.83

Insider Buying % (6 Mo)

Distance to 52-Week High

46.54%

Distance to 52-Week Low

16.79%

EARNINGS SURPRISE %

2.68%

50-DAY SMA

$60.33

200-DAY SMA

$68.90

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.